FT014
Focal segmental glomerulosclerosis
PreclinicalActive
Key Facts
About Certa Therapeutics
Australian precision‑medicine biotech targeting fibrosis through GPR68 inhibition.
View full company profileTherapeutic Areas
Other Focal segmental glomerulosclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| FSGS Development Program | Delta4 AI | Preclinical |